A Unified Platform for Precision Diagnostics and Patient Stratification
A functional diagnostic platform that guides patient stratification and treatment selection across oncology and infectious diseases.
About PAN Biologics
Powering Diagnostics and Targeted Therapy from One Platform
PAN Biologics is a spinout from Oak Ridge National Laboratory, Department of Energy (DOE) developing a unified bioengineering platform that enables both functional diagnostics and targeted therapeutics across cancer and infectious diseases with immediate applications in outbreak response and public health preparedness.
About PAN Biologics
Powering Diagnostics and Targeted Therapy from One Platform
PAN Biologics is a spinout from Oak Ridge National Laboratory, Department of Energy (DOE) developing a unified bioengineering platform that enables both functional diagnostics and targeted therapeutics across cancer and infectious diseases with immediate applications in outbreak response and public health preparedness.
Our Technology
A unified biological platform enabling functional diagnostics and targeted therapeutic modalities for cancer and infectious diseases.
Patient Stratification
Precision selection of patients for treatment
- Efficacy in patients resistant to current modalities.
Diagnostics
Functional marker detection
- Real-time monitoring of protein interaction dynamics.
- Clinically actionable, minimally invasive.
Mechanism-Based Drug Screening
Accelerating Drug Development
- Validates therapeutic impact.
- Functional, phenotypic, and receptor-level assays.
- Ideal for pharma & biotech partnerships.
Our Team
PAN Biologics was founded by Dr. Kuntal De, a scientist with a research background from the Cleveland Clinic, The Ohio State University’s James Cancer Hospital, and Oak Ridge National Laboratory. Dr. De launched PAN Biologics to bring cutting-edge science out of the lab and into the clinic, focusing on precision therapies for treatment resistant cancers and infectious disease. Our team brings deep expertise in oncology, molecular biology, and radiopharmaceutical development, combining academic excellence with a passion for real-world impact.
From molecular insight to therapeutic impact.
Our pipeline reflects a focused effort to disrupt the oncogenic signaling axis and viral internalization through novel peptide therapeutics, nanobody constructs, and targeted delivery systems.
| Product | Program | Target Identification | Research and development | Preclinical clinical |
|---|---|---|---|---|
PB001
Cancer
PB002
Cancer
PB003
Cancer
PB004
Cancer
PB005
Antiviral
Kuntal De PhD
CEO and Founder
Christopher Brett
Clinical Advisor
Gregg Bostick
Director, TSBDC Business Advisor
Debasish Sen
Drug Discovery & In Vivo Model Lead
Mahesh Aitha
Biophysics & Structural Bio-Advisor
Libère Ndacayisaba
Computational & AI Biologist
News & Publication
Science-Driven and Nationally Recognized
A. “Basic to Breakthrough” research article by DOE (Department of Energy) Office of Science.
B. Research was selected as one of the top 10 News highlights in the whole academic year 2022 and 2023 from ORNL (Nation’s largest multidisciplinary science program).
C. How plant biology research could inform COVID-19 treatments.
D. Government Media Spotlight: The Science Behind PAN Biologics”
Targeted diagnostics and therapies for treatment-resistant cancer and infectious diseases
Primary link
- About Us
- Technology
- Team
- Why Choose Us
- Partners
- News & Publication
Official Contact
- dek@panbiologics.org
- Knoxville, TN